Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.

Long-acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) provides an alternative to daily therapy for people with HIV (PWH) with virologic suppression. Although genotypic testing is recommended before switching, its real-world clinical value is unclear. We assessed outcomes after switching...

Full description

Bibliographic Details
Authors: Buzón L, Bernardino JI, Galindo Puerto MJ, Martín-Torres J, Alemán Valls MR, Torralba González de Suso M, Díaz de Santiago A, Fanjul F, Rodríguez A, Cabello Úbeda A, Pedrero-Tomé R, Crusells Canales MJ, Calzado Isbert S, Aguilera García M, Hidalgo Tenorio C, Morano L, Vinuesa García D, de Andrés David C, Bernal Morell E, Martínez Álvarez RM, Cabello Clotet N, Tiraboschi J, Gimeno García A, Vivancos MJ, Troya J
Format: article
Status:Published version
Publication Date:2025
Country:España
Institution:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repository:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p6843
Online Access:https://i3pt.portalinvestigacion.com/publicaciones/6843
Access Level:Open access
Keyword:HIV Infections, antiretroviral therapy, cabotegravir, genotypic resistance test, long-acting agents, rilpivirine
id ES_e4aa0ec4e6889b6328c42ad9b6e81da0
oai_identifier_str oai:i3pt.fundanetsuite.com:p6843
network_acronym_str ES
network_name_str España
repository_id_str
spelling Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.Buzón LBernardino JIGalindo Puerto MJMartín-Torres JAlemán Valls MRTorralba González de Suso MDíaz de Santiago AFanjul FRodríguez ACabello Úbeda APedrero-Tomé RCrusells Canales MJCalzado Isbert SAguilera García MHidalgo Tenorio CMorano LVinuesa García Dde Andrés David CBernal Morell EMartínez Álvarez RMCabello Clotet NTiraboschi JGimeno García AVivancos MJTroya JHIV Infections, antiretroviral therapy, cabotegravir, genotypic resistance test, long-acting agents, rilpivirineLong-acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) provides an alternative to daily therapy for people with HIV (PWH) with virologic suppression. Although genotypic testing is recommended before switching, its real-world clinical value is unclear. We assessed outcomes after switching to LAI CAB+RPV with or without available genotypes in the Spanish RELATIVITY cohort.LIPPINCOTT WILLIAMS & WILKINS2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/6843AIDSISSN: 02699370ISSNe: 14735571reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:i3pt.fundanetsuite.com:p68432026-06-21T15:30:37Z
dc.title.none.fl_str_mv Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.
title Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.
spellingShingle Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.
Buzón L
HIV Infections, antiretroviral therapy, cabotegravir, genotypic resistance test, long-acting agents, rilpivirine
title_short Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.
title_full Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.
title_fullStr Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.
title_full_unstemmed Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.
title_sort Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.
dc.creator.none.fl_str_mv Buzón L
Bernardino JI
Galindo Puerto MJ
Martín-Torres J
Alemán Valls MR
Torralba González de Suso M
Díaz de Santiago A
Fanjul F
Rodríguez A
Cabello Úbeda A
Pedrero-Tomé R
Crusells Canales MJ
Calzado Isbert S
Aguilera García M
Hidalgo Tenorio C
Morano L
Vinuesa García D
de Andrés David C
Bernal Morell E
Martínez Álvarez RM
Cabello Clotet N
Tiraboschi J
Gimeno García A
Vivancos MJ
Troya J
author Buzón L
author_facet Buzón L
Bernardino JI
Galindo Puerto MJ
Martín-Torres J
Alemán Valls MR
Torralba González de Suso M
Díaz de Santiago A
Fanjul F
Rodríguez A
Cabello Úbeda A
Pedrero-Tomé R
Crusells Canales MJ
Calzado Isbert S
Aguilera García M
Hidalgo Tenorio C
Morano L
Vinuesa García D
de Andrés David C
Bernal Morell E
Martínez Álvarez RM
Cabello Clotet N
Tiraboschi J
Gimeno García A
Vivancos MJ
Troya J
author_role author
author2 Bernardino JI
Galindo Puerto MJ
Martín-Torres J
Alemán Valls MR
Torralba González de Suso M
Díaz de Santiago A
Fanjul F
Rodríguez A
Cabello Úbeda A
Pedrero-Tomé R
Crusells Canales MJ
Calzado Isbert S
Aguilera García M
Hidalgo Tenorio C
Morano L
Vinuesa García D
de Andrés David C
Bernal Morell E
Martínez Álvarez RM
Cabello Clotet N
Tiraboschi J
Gimeno García A
Vivancos MJ
Troya J
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv HIV Infections, antiretroviral therapy, cabotegravir, genotypic resistance test, long-acting agents, rilpivirine
topic HIV Infections, antiretroviral therapy, cabotegravir, genotypic resistance test, long-acting agents, rilpivirine
description Long-acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) provides an alternative to daily therapy for people with HIV (PWH) with virologic suppression. Although genotypic testing is recommended before switching, its real-world clinical value is unclear. We assessed outcomes after switching to LAI CAB+RPV with or without available genotypes in the Spanish RELATIVITY cohort.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://i3pt.portalinvestigacion.com/publicaciones/6843
url https://i3pt.portalinvestigacion.com/publicaciones/6843
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv LIPPINCOTT WILLIAMS & WILKINS
publisher.none.fl_str_mv LIPPINCOTT WILLIAMS & WILKINS
dc.source.none.fl_str_mv AIDS
ISSN: 02699370
ISSNe: 14735571
reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422611426967552
score 15.812429

Similar Items